Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2017 | Pages:
70 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)
The global narcolepsy therapeutics market is expected to reach USD 3.85 billion by 2025, according to a new report by Grand View Research, Inc. The increasing awareness about this sleep disorder among public and healthcare providers is a key factor contributing to the market growth. The Narcolepsy Network has estimated that out of every 2,000 people 1 is afflicted by this condition. Moreover, Narcolepsy UK states that around 25% patients are identified and remaining 75% are untreated as they remain undiagnosed or are misdiagnosed, which is alarming. Some organizations and networks are constantly working to spread awareness about this condition among the patients and physicians. Further key findings from the report suggest : • The narcolepsy therapeutics market is expected to grow substantially owing to the worldwide increasing incidence of this disorder. • Narcolepsy with cataplexy was identified as the largest type segment in 2016. It is expected to retain its position throughout the forecast period owing to the rising cases of cataplexy in patients suffering from narcolepsy. • Narcolepsy without cataplexy is likely to witness the fastest growth over the forecast period due to increasing awareness about Excessive Daytime Sleepiness (EDS) through various mediums, such as awareness campaigns • Sodium oxybate dominated the product segment in terms of revenue share in the year 2016, and it is also expected to be the fastest growing segment over the forecast period. Drugs belonging to this class have higher costs and favorable coverage policies. • Xyrem is the only FDA-approved drug in this category and is extensively prescribed for the treatment of cataplexy and EDS. American Academy of Sleep Medicine (ASSM) recommends it as a standard treatment of this disorder. • Europe dominated the regional market in terms of revenue share in 2016 because of increase in capital investments and existence of established healthcare infrastructure along with a large target population • The H1N1 influenza postvaccination pandemic of the year 2009 has resulted in growth of number of narcolepsy patients • Asia Pacific is likely to exhibit fastest growth during the forecast period due to the rising healthcare expenditure in this region, rising awareness among people, highest prevalence in Japan, and presence of emerging economies such as China & India • Some of the major market players are Jazz Pharmaceuticals PLC;Teva Pharmaceutical Industries Ltd.;Graymark Healthcare, Inc.;Addrenex Pharmaceuticals, Inc.; and BIOPROJET. • Mergers and acquisitions are strategic initiatives undertaken by these market players in an attempt to remain competitive. In addition, companies are expanding their geographical presence to untapped markets.
Table of Contents
Chapter 1 Research Methodology & Scope
1.1 Information Procurement
1.1.1 Purchased database:
1.1.2 GVR's internal database
1.2 Research Methodology
1.3 Geographic scope & assumptions
1.4 Region-wise market calculation
1.4.1 Region-wise market: Base estimates
1.4.2 Global market: CAGR calculation
1.5 Region-based segment share calculation
1.6 List of Secondary Sources
Chapter 2 Executive Summary
2.1 Market Snapshot
Chapter 3 Narcolepsy Therapeutics Market Variables, Trends & Scope
3.1 Market segmentation & scope
3.1.1 Market driver analysis
3.1.1.1 Increasing global prevalence of narcolepsy
3.1.1.2 Narcolepsy awareness programs and services
3.1.1.3 Presence of reimbursement policies regarding narcolepsy
3.1.2 Market restraint analysis
3.1.2.1 Adverse effects and risks related to narcolepsy drugs
3.1.2.2 Delayed diagnosis or misdiagnosis
3.3 Narcolepsy therapeutics - SWOT Analysis, By Factor (Political & Legal, Economic, and Technological)
3.4 Industry Analysis - Porter's
Chapter 4 M Narcolepsy Therapeutics Market: Type Estimates & Trend Analysis
4.1 Narcolepsy Therapeutics Market: Type Movement Analysis
4.2 Narcolepsy With Cataplexy
4.2.1 Narcolepsy with cataplexy market, 2014 - 2025 (USD Million)
4.3 Narcolepsy Without Cataplexy
4.3.1 Narcolepsy without cataplexy market, 2014 - 2025 (USD Million)
4.4 Secondary Narcolepsy
4.4.1 Secondary narcolepsy market, 2014 - 2025 (USD Million)
Chapter 5 Narcolepsy Therapeutics Market: Product Estimates & Trend Analysis
5.1 Narcolepsy Therapeutics Market: Product Movement Analysis
5.2 Central nervous system stimulants
5.2.1 Central nervous system stimulants market, 2014 - 2025 (USD Million)
5.3 Sodium Oxybate
5.3.1 Sodium Oxybate market, 2014 - 2025 (USD Million)
5.4 Selective Serotonin Reuptake Inhibitor (SSRI)
5.4.1 Selective serotonin reuptake inhibitor market, 2014 - 2025 (USD Million)
5.5 Tricyclic Antidepressants
5.5.1 Tricyclic antidepressants market, 2014 - 2025 (USD Million)
5.6 Other Narcolepsy Drugs
5.6.1 Other narcolepsy drugs market, 2014 - 2025 (USD Million)
Chapter 6 Narcolepsy Therapeutics: Regional Estimates & Trend Analysis, by Drug Type
6.1 Narcolepsy Therapeutics Market Share by Region, 2016 & 2025
6.2 North America
6.2.1 North America narcolepsy therapeutics market, 2014 - 2025 (USD Million)
6.3 Europe
6.3.1 Europe narcolepsy therapeutics market, 2014 - 2025 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific narcolepsy therapeutics market, 2014 - 2025 (USD Million)
6.5 Latin America
6.5.1 Latin America narcolepsy therapeutics market, 2014 - 2025 (USD Million)
6.6 MEA
6.6.1 MEA narcolepsy therapeutics market, 2014 - 2025 (USD Million)
Chapter 7 Competitive Landscape
7.1 Strategy framework
7.2 Company Profiles
7.2.1 Addrenex Pharmaceuticals, Inc.
7.2.1.1 Company Overview
7.2.1.2 Product benchmarking
7.2.1.3 Strategic initiatives
7.2.2 Teva Pharmaceutical Industries Ltd.
7.2.2.1 Company overview
7.2.2.1 Financial performance
7.2.2.2 Product benchmarking
7.2.2.3 Strategic initiatives
7.2.3 Jazz Pharmaceuticals PLC
7.2.3.1 Company overview
7.2.3.2 Product benchmarking
7.2.3.3 Strategic initiatives
7.2.4 Graymark Healthcare, Inc.
7.2.4.1 Company overview
7.2.4.2 Product benchmarking
7.2.4.3 Strategic initiatives
7.2.5 Arena Pharmaceuticals, Inc.
7.2.5.1 Company overview
7.2.5.2 Financial performance
7.2.5.3 Product benchmarking
7.2.5.4 Strategic Initiatives
7.2.6 BIOPROJET
7.2.6.1 Company overview
7.2.6.2 Product benchmarking
7.2.6.3 Strategic initiatives
7.2.7 Shire
7.2.7.1 Company overview
7.2.7.2 Financial performance
7.2.7.3 Product benchmarking
7.2.7.4 Strategic initiatives
7.2.8 Ligand Pharmaceuticals, Inc.
7.2.8.1 Company overview
7.2.8.2 Financial performance
7.2.8.3 Product benchmarking
7.2.8.4 Strategic initiatives
List of Tables TABLE 1 North America narcolepsy therapeutics market, by type, 2014 - 2025 (USD Million) TABLE 2 North America narcolepsy therapeutics market, by product, 2014 - 2025 (USD Million) TABLE 3 Europe narcolepsy therapeutics market, by type, 2014 - 2025 (USD Million) TABLE 4 Europe narcolepsy therapeutics market, by product, 2014 - 2025 (USD Million) TABLE 5 Asia Pacific narcolepsy therapeutics market, by type, 2014 - 2025 (USD Million) TABLE 6 Asia Pacific narcolepsy therapeutics market, by product, 2014 - 2025 (USD Million) TABLE 7 Latin America narcolepsy therapeutics market, by type, 2014 - 2025 (USD Million) TABLE 8 Latin America narcolepsy therapeutics market, by product, 2014 - 2025 (USD Million) TABLE 9 MEA narcolepsy therapeutics market, by type, 2014 - 2025 (USD Million) TABLE 10 MEA narcolepsy therapeutics market, by product, 2014 - 2025 (USD Million)
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
